Save on Amivantamab-VMJW with Coupons, Discounts & Savings Programs

Amivantamab-VMJW is available as a 350 mg/7 mL (50 mg/mL) solution that is an injection for IV use.

Amivantamab-VMJW is an EGFR and MET inhibitor that is used to treat:

• Locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations in people who have previously received platinum-based chemotherapy

Amivantamab-VMJW is an EGFR and MET inhibitor. It’s a bispecific monoclonal antibody that targets proteins on tumor cells called EGFR and MET. MET and EGFR are proteins in the body involved in signaling cells to grow and divide.

In certain lung cancers, mutations (changes) in specific genes lead to abnormal MET and EGFR proteins. This causes cells to grow out of control. Amivantamab-VMJW works by attaching (binding) to EGFR and MET proteins, blocking the tumor from growing, and alerting the immune system to destroy those abnormal cells.

Amivantamab-VMJW is given as an intravenous (IV) infusion. The typical dose of Amivantamab-VMJW depends on your weight:

• Weight less than 80 kg (176 lbs): The recommended dose is 1050 mg
• Weight 80 kg (176 lbs) or more: The recommended dose is 1400 mg
• The dosing schedule for Amivantamab-VMJW is in 28-day cycles
• During your first cycle, you’ll receive an infusion on days 1 and 2, then weekly on day 8, day 15, and day 22.
• After your first cycle, you’ll get the infusion every other week (day 1 and day 15 of each cycle)

Amivantamab-VMJW is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Amivantamab-VMJW:

• Rash
• Infusion reaction (e.g., trouble breathing, chills, nausea)
• Nail infection
• Muscle, bone, or joint pain
• Shortness of breath
• Nausea
• Fatigue
• Swelling
• Mouth sores
• Cough
• Constipation
• Vomiting

Serious side effects are rare with Amivantamab-VMJW. Contact your healthcare provider immediately if you experience any of the following.

• Infusion reactions: hives, breathing problems, dizziness, chills, chest pain, swelling of the mouth or lips
• Lung damage: cough, shortness of breath, fever
• Severe skin reactions: burning, redness, rashes, blisters, or peeling
• Eye problems: eye pain, redness, dryness, or itching; vision changes

• There are no major drug interactions listed for Amivantamab-VMJW. However, always let your physician and pharmacist know about any other medications or supplements (including prescribed and over-the-counter medications, vitamins, and dietary or herbal supplements) that you are currently taking

Various FDA-approved generic manufacturers

Based on its mechanism of action and findings from animal models, Amivantamab-VMJW can cause fetal harm when administered to a pregnant woman. If you can become pregnant, you should to use effective contraception during treatment and for 3 months after the last dose of Amivantamab-VMJW.

• Rybrevant